Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
Background: OXi4503 is a tubulin-binding vascular disrupting agent that has recently completed a Cancer Research UK-sponsored phase I trial. Preclinical studies demonstrated early drug-induced apoptosis in tumour endothelial cells at 1-3 h and secondary tumour cell necrosis between 6 and 72 h. Metho...
প্রধান লেখক: | Cummings, J, Zweifel, M, Smith, N, Ross, P, Peters, J, Rustin, G, Price, P, Middleton, MR, Ward, T, Dive, C |
---|---|
বিন্যাস: | Journal article |
ভাষা: | English |
প্রকাশিত: |
2012
|
অনুরূপ উপাদানগুলি
অনুরূপ উপাদানগুলি
-
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial.
অনুযায়ী: Cummings, J, অন্যান্য
প্রকাশিত: (2012) -
Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.
অনুযায়ী: Patterson, D, অন্যান্য
প্রকাশিত: (2012) -
Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection.
অনুযায়ী: Stratford, MR, অন্যান্য
প্রকাশিত: (2011) -
Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection
অনুযায়ী: Stratford, M, অন্যান্য
প্রকাশিত: (2011) -
4503 Adaptation of Motor Action in Children with Hemiplegic Cerebral Palsy
অনুযায়ী: Katherine Dimitropoulou, অন্যান্য
প্রকাশিত: (2020-06-01)